drugset / Trial / NCT05043298
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label Phase Ia/Ib trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of IBI360 monotherapy in Advanced or Metastatic Solid Tumors
Timeline
- Start
- 2021-10-27
- Primary completion
- 2023-08-30
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI 360 | Unknown | — | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |